Case Reports in Oncology最新文献

{"title":"Parathyroid Hormone-Related Protein-Producing Adenocarcinoma Suspicious of Lung Cancer: A Case Report.","authors":"Masahiro Hirabayashi, Tomonobu Koizumi, Daichi Nakajima, Shuko Azegami, Hajime Midorikawa, Nami Kitagawa, Hideaki Hamano, Tatsunori Chino, Maki Ohya","doi":"10.1159/000540418","DOIUrl":"10.1159/000540418","url":null,"abstract":"<p><strong>Introduction: </strong>Lung adenocarcinoma with parathyroid hormone (PTH)-related hypercalcemia is uncommon.</p><p><strong>Case presentation: </strong>A 69-year-old man was admitted to our hospital due to anorexia and fatigue. Serum calcium (15.0 mg/dL) and carcinoembryonic antigen (361.7 ng/mL) were extremely high, and PTH-related protein (PTH-rP) also elevated (16.7 pmol/L). Systemic computed tomography revealed multiple enlarged lymph nodes and disseminated peritoneal nodules, with irregularly shaped nodules in the upper lobe in the left lung. Ultrasound-guided biopsy from the axillary lymph node revealed adenocarcinoma. Immunohistological staining showed the tumor cells to be positive for cytokeratin 7 and PTH-rP and negative for cytokeratin 20 and thyroid transcription factor-1. Although the primary origin remains undetermined despite detailed examinations, possible primary tumor was considered to be lung adenocarcinoma in the present case. The serum calcium level was reduced by denosumab, but the patient died 20 days after admission.</p><p><strong>Conclusion: </strong>The present case demonstrated the importance of considering oncological emergency, such as hypercalcemia and/or PTH-rP-producing hypercalcemia, in patients with adenocarcinoma.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Small Bowel Adenocarcinoma with Metastatic Ovarian Tumor in a Pregnant Woman.","authors":"Yutaro Takahashi, Takayoshi Iijima, Yumi Ishidera, Yuichi Imai, Taichi Mizushima, Daisuke Utsunomiya, Noritoshi Kobayashi, Yasushi Ichikawa, Shingo Kato, Jotaro Harada, Etsuko Miyagi","doi":"10.1159/000540524","DOIUrl":"10.1159/000540524","url":null,"abstract":"<p><strong>Introduction: </strong>Primary small bowel carcinoma in pregnant women is extremely rare. Small bowel cancer is difficult to diagnose because of its rarity, lack of specific clinical symptoms, and particular anatomical features. We experienced a case of primary small bowel adenocarcinoma with ovarian metastasis during pregnancy. This is the first reported case of a patient with small bowel adenocarcinoma whose pregnancy continued to term and ended in delivery.</p><p><strong>Case presentation: </strong>A 32-year-old pregnant woman developed abdominal pain, and imaging examination revealed an ovarian tumor at 29 weeks of gestation. We performed laparotomy and resected the ovarian tumor, which was initially suspected to be primary ovarian cancer. The patient continued the pregnancy to term. A detailed examination of the abdominal cavity during cesarean delivery at 37 weeks revealed that the primary lesion was located in the small bowel.</p><p><strong>Conclusion: </strong>It is important to recognize that the small bowel may be the primary site of metastatic ovarian cancer. Detailed and careful examination is necessary to diagnose small bowel cancer during pregnancy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case Report.","authors":"Ayatsugu Otsuka, Norifumi Sawada, Ryosuke Suda, Fumiakira Yano, Takuya Osada, Yuko Otake, Hiroshi Shimura, Takanori Mochizuki, Daiki Harada, Junko Goto, Tomomi Watanabe, Tadatsugu Hosokawa, Satoru Kira, Kyoichiro Tsuchiya, Takeshi Moriguchi, Takahiko Mitsui","doi":"10.1159/000540354","DOIUrl":"10.1159/000540354","url":null,"abstract":"<p><strong>Introduction: </strong>Enfortumab vedotin (EV) is an antibody-drug conjugate combining a monoclonal antibody targeting nectin-4 with a highly potent microtubule disrupting agent. EV is expected to be a candidate for the third-line treatment for urothelial carcinoma previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors. Very few cases of patients experienced hyperglycemia of unknown cause.</p><p><strong>Case presentation: </strong>We describe a 72-year-old Asian man with mild obesity, type 2 diabetes, hyperlipidemia, hypertension, and chemo-resistant metastatic urothelial carcinoma. He developed hyperglycemia and febrile neutropenia after 3 doses of EV. He had hyperglycemia of 489 mg/dL and was started on continuous intravenous insulin infusion (CVII). The patient's intravenous insulin requirements peaked at 316 units per day. He also developed febrile neutropenia and consequent sepsis caused acute kidney injury. Continuous hemodialysis filtration (CHDF) together with antibiotics were started to treat the septic condition. The blood glucose level gradually decreased after CHDF treatment and CHDF was continued for 14 days. The timing of liberation from CHDF correlated with the elimination half-life of EV of 3.4 days. CVII was treated for 26 days and the patient was finally released from the intensive care unit.</p><p><strong>Conclusion: </strong>This case indicates that the uncontrollable hyperglycemia induced by EV during metastatic urothelial carcinoma treatment is effectively managed with CVII and CHDF until the elimination of the adverse effect of EV.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Synchronous Multiple Primary Early-Stage Lung Adenocarcinoma with Concomitant MET Exon 14 Skipping, PIK3CA and KRAS Mutations: A Case Report.","authors":"Yongjing Zhang, Qiqi Gao","doi":"10.1159/000540355","DOIUrl":"10.1159/000540355","url":null,"abstract":"<p><strong>Instruction: </strong>Synchronous multiple primary lung cancer (sMPLC) constitutes a distinct subtype of NSCLC, where accurate diagnosis and prognostic evaluation remain challenging.</p><p><strong>Case presentation: </strong>The case involves a 70-year-old male patient admitted to the hospital due to bilateral pulmonary nodules. The patient underwent staged resection. Molecular pathological examination revealed that tumor A harbored concurrent mutations in MET exon 14 skipping and PIK3CA (p.E545K), while tumor B exhibited a KRAS exon 2 (p.G12S/D) mutation. Postoperatively, the patient demonstrated a favorable recovery, with no evidence of recurrence for 1 year.</p><p><strong>Conclusion: </strong>This study presents a case of sMPLC in early-stage lung cancer, illustrating the genetic heterogeneity in early-stage lung adenocarcinoma and underscoring the significance of precise evaluation of sMPLC and intrapulmonary metastases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-Escalated Adjuvant Treatment for Advanced MMR Deficient Mixed Endometrioid/Clear Cell Endometrial Carcinoma with PD-1 Inhibition Alone: A Case Report.","authors":"Danielle M Blemur, Ravali A Reddy, Susan M Lang, Malte Renz","doi":"10.1159/000540357","DOIUrl":"10.1159/000540357","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced mixed epithelial endometrial carcinomas are rare high-grade cancers with a poor prognosis. A clear cell component infers relative chemotherapy insensitivity, likely further increased by p53 wild type status and MMR deficiency. PD-1 inhibition for MMR deficient endometrial cancers has been recently added to first-line adjuvant treatment in combination with platinum-based chemotherapy. Information on de-escalation of adjuvant treatment to PD-1 inhibition alone without chemotherapy is sparse.</p><p><strong>Case presentation: </strong>Here, we present a patient with advanced stage mixed epithelial endometrial carcinoma, a clear cell component and MMR deficiency who underwent de-escalated adjuvant treatment with PD-1 inhibition alone without simultaneous chemotherapy.</p><p><strong>Conclusion: </strong>Histotype-agnostic adjuvant monotherapy with checkpoint immune inhibitors alone appears to be a highly effective even in the rare mixed endometrial carcinomas if MMR protein deficient as described in this case report.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report.","authors":"Takayuki Hirano, Kousuke Yonezawa, Takashi Kawahara, Nobuhiko Mizuno, Hiroyuki Hayashi, Yuta Karibe, Jun Asano, Shusei Fusayasu, Kazuhide Makiyama, Hiroji Uemura, Junichi Ohta, Masatoshi Moriyama","doi":"10.1159/000540419","DOIUrl":"10.1159/000540419","url":null,"abstract":"<p><strong>Introduction: </strong>There have been few reports of patients for whom a cancer gene panel test for solid tumors revealed the simultaneous presence of BRCA mutation and microsatellite instability (MSI)-high status. BRCA mutations have been reported in 13% of castration-resistant prostate cancer (CRPC) patients, and 3.1% of prostate cancer cases are MSI-high/mismatch repair deficient.</p><p><strong>Case presentation: </strong>A 71-year-old man with a history of urinary retention was referred to our department for clinically suspected prostate cancer and a high prostate-specific antigen (PSA) level (141 ng/mL). MRI revealed features of prostate cancer invading the bladder, seminal vesicles, and rectum. A histopathological examination of a transperineal needle biopsy specimen obtained from the prostate revealed adenocarcinoma. Bone scintigraphy revealed multiple metastases. The patient was treated with abiraterone acetate combined with androgen deprivation therapy followed by local radiation. Rectal wall thickening and lymph node metastasis were also observed, and docetaxel was administered. A cancer gene panel test was positive results for BRCA2 mutation with a MSI-high. After six courses of docetaxel, lymph node enlargement was observed and olaparib was initiated. Two months later, the metastatic lesions showed enlargement and the PSA level increased. Subsequently, pembrolizumab was administered. At 2 to the patient months after the initiation of pembrolizumab administration, PSA levels decreased to <0.025 ng/mL and the rectal lesions and lymph node metastases disappeared. The patient was continuing to receive pembrolizumab without any apparent adverse events or exacerbations, 9 months after initiation.</p><p><strong>Conclusion: </strong>We herein report a case in which pembrolizumab treatment resulted in a complete response in a CRPC patient with both a BRCA2 mutation and an MSI-high status.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful <i>EGFR</i> Mutation Detection in Cytological Specimens of Lung Cancer with Challenging Biopsies by Integrating Virtual Bronchoscopy Navigation and Endobronchial Ultrasound Guidance with Highly Sensitive Next-Generation Sequencing: A Case Report.","authors":"Yasuhiro Umeyama, Hiroshi Soda, Hiroaki Senju, Ryosuke Ogata, Mizuki Iwanaga, Hiroko Hayashi, Hirokazu Taniguchi, Shinnosuke Takemoto, Takahiro Takazono, Noriho Sakamoto, Yuichi Fukuda, Hiroshi Mukae","doi":"10.1159/000540356","DOIUrl":"10.1159/000540356","url":null,"abstract":"<p><strong>Introduction: </strong>This case report presents the successful detection of an <i>EGFR</i> exon 19 deletion using virtual bronchoscopic navigation (VBN) and endobronchial ultrasound with guide sheath (EBUS-GS) brushing, integrated with highly sensitive next-generation sequencing (NGS), even in challenging biopsy scenarios. The growing prevalence of driver gene alterations in non-small cell lung cancer necessitates effective bronchoscopic technology and reliable multiplex gene NGS panels. However, data regarding the optimal bronchoscopic techniques when using highly sensitive NGS panels are limited. Herein, we report a case utilizing VBN-guided EBUS-GS brushing as an exploratory approach to address this challenge.</p><p><strong>Case presentation: </strong>A 71-year-old man was evaluated for a band-like lesion near the left pleura during spinal cord infarction. Transbronchial specimens were obtained from lesions invisible on conventional chest radiography and X-ray fluoroscopy using VBN and EBUS-GS brushing. Cytological brushing specimens revealed lung adenocarcinoma, and highly sensitive NGS identified an <i>EGFR</i> exon 19 deletion. He was diagnosed with stage IB disease and underwent radical radiotherapy owing to his fragile condition. If recurrence occurs, the patient will be treated with an EGFR inhibitor.</p><p><strong>Conclusion: </strong>VBN-guided EBUS-GS brushing, a minimally invasive approach, combined with highly sensitive NGS has the potential to provide accurate molecular diagnoses to more patients with lung cancer, thereby offering opportunities for personalized treatment. Our findings warrant further investigation to determine optimal bronchoscopic technologies for obtaining tumor specimens.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Treatment for Locally Advanced Mucinous Breast Cancer.","authors":"Masanori Hayashi, Shoji Oura, Haruka Nishiguchi","doi":"10.1159/000539717","DOIUrl":"10.1159/000539717","url":null,"abstract":"<p><strong>Background: </strong>Due to its indolent biology and high estrogen receptor positivity of mucinous breast cancer, vast majority of locally advanced mucinous breast cancer (LABC) are treated with first-line endocrine therapy.</p><p><strong>Case presentation: </strong>A 50-year-old woman was referred to our hospital for the treatment of her huge breast tumor. Computed tomography showed an oval solid tumor, 17 cm in size, and lymph node swelling in both the axilla and parasternum. Pathological study of the core needle biopsy specimen showed the tumor to be luminal mucinous carcinoma. After the failure of endocrine therapy aiming for tumor regression, the patient received sequential chemotherapy to get favorable local control, leading to marked tumor shrinkage. Axillar and parasternal lymph nodes, however, remained unchanged in size. The patient further underwent mastectomy and regional lymph node dissection including removal of the still enlarged parasternal lymph nodes followed by covering of the large skin defect with the latissimus dorsi musculocutaneous (LDMC) flap using a spindle skin island, 15 × 8 cm in size. Postoperative pathological study showed sparse cancer cell remnants with abundant mucus in both the primary tumor and the dissected lymph nodes. The patient has been well without any recurrences on endocrine therapy for 21 months.</p><p><strong>Conclusion: </strong>Breast oncologists should note that multidisciplinary treatment including preoperative chemotherapy and skin defect covering using LDMC flap can give favorable local control even to breast cancer patients with LABC.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apocrine Adenoma of the Breast Showing Unique Image Findings.","authors":"Senri Kondo, Shoji Oura","doi":"10.1159/000539644","DOIUrl":"10.1159/000539644","url":null,"abstract":"<p><strong>Introduction: </strong>Apocrine adenoma of the breast is extremely rare and its typical images remain uncertain.</p><p><strong>Case presentation: </strong>A 66-year-old woman was incidentally found of her left breast tumor with computed tomography for ascending colon cancer staging work. Mammography showed a well-demarcated oval mass. Ultrasonography showed an oval mass with indistinct borders, internal iso-echoes with multiple high echo spots, and unchanged posterior echoes. Magnetic resonance imaging of the mass showed a hypo-intense pattern both on T1- and T2-weighted images and a long-lasting rim enhancement pattern up to the late phase on time-signal intensity images. Probably due to the inappropriate tissue sampling, no definitive pathological diagnosis was obtained with core needle biopsy, forcing us to do lumpectomy of the breast mass at the time of colon cancer surgery. The resected breast mass was hard, clearly demarcated, and 8 mm in size. Cut surface of the mass was flesh-colored and had multiple white spots. Pathological study showed dense predominantly oval glandular ducts with luminal apocrine cell layers, outer myoepithelium cell layers, and slight fibrosis. Glandular cavities on pathology well matched to the white spots on macroscopic view, seemed vacant in a cyst-like fashion, and had aggregated foamy histiocytes in some of them. These pathological findings led us to the diagnosis of apocrine adenoma of the breast.</p><p><strong>Conclusion: </strong>Diagnostic physicians should note this extremely rare breast disorder and its image findings.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Survival in Hepatocellular Carcinoma following Second-Line Tumor Treating Fields Therapy and Sorafenib: A Case Report.","authors":"Marisa Torres Velasco, Rafael Álvarez Gallego, Paloma Peinado, Cesar Muñoz Gregorio, Lisardo Ugidos, Marcial García Morillo, Emilio Vicente, Yolanda Quijano, Susana Prados, Enrique de la Fuente, Antonio Cubillo Gracián","doi":"10.1159/000539719","DOIUrl":"10.1159/000539719","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is an aggressive solid tumor associated with high mortality. Surgery is the main treatment consideration for early disease, but patients who present with locally advanced or metastatic HCC at diagnosis have limited treatment options. There has been great progress in locoregional, immunotherapy, and targeted treatments for advanced HCC. Standard of care for HCC has changed due to results demonstrating safety and efficacy in phase 3 studies, namely, for atezolizumab concomitant with bevacizumab. Nonetheless, additional therapeutic approaches are still warranted to further increase overall survival in HCC. A first-in-class treatment option investigated in patients with HCC is Tumor Treating Fields (TTFields) therapy, which is delivered locoregionally to the tumor site from a portable medical device. TTFields are electric fields that interfere with critical cancer cell processes, hindering tumor progression.</p><p><strong>Case presentation: </strong>Here, we report on a case study of a 62-year-old male patient with HCC receiving TTFields concomitant with sorafenib as second-line therapy. Although the patient experienced adverse events with previous nivolumab, they achieved a complete response and continued on treatment for 51 months until disease progression, which led to treatment cessation. We report that during 39 months of subsequent treatment with TTFields therapy and sorafenib, the patient experienced a good quality of life, low systemic toxicity, and stable disease following a partial response.</p><p><strong>Conclusions: </strong>These promising findings, along with those of the pilot phase 2 HEPANOVA clinical study, warrant further investigation of TTFields therapy in HCC.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}